Text Size
19 studies found for:    weill | Open Studies | "Liver Diseases"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium
Condition: Hepatic Fibrosis
Intervention: Procedure: MRI of liver
2 Unknown † Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)
Condition: Hepatitis C
Intervention: Drug: Telaprevir
3 Unknown † Effect of Large Volume Paracentesis on Fatigue in Cirrhosis
Conditions: Ascites;   Fatigue;   Cirrhosis
Intervention:
4 Unknown † The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
Conditions: Hepatic Encephalopathy;   Hepatitis C;   Liver Cirrhosis
Intervention: Drug: Rifaximin (drug)
5 Recruiting Armodafinil for Patients Starting Hepatitis C Virus Treatment
Condition: Hepatitis C
Interventions: Drug: Armodafinil;   Drug: Placebo
6 Unknown † Rifaximin Versus Lactulose in Renal Failure
Conditions: Liver Cirrhosis;   Renal Failure
Interventions: Drug: Rifaximin;   Drug: Lactulose
7 Unknown † Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP)
Conditions: Spontaneous Bacterial Peritonitis;   Cirrhosis
Interventions: Drug: Standard Care;   Drug: Experimental
8 Recruiting Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Condition: Hepatitis C Virus
Interventions: Drug: Asunaprevir (ASV);   Drug: Daclatasvir (DCV);   Drug: PBO matching ASV;   Drug: Placebo (PBO) matching DCV;   Drug: Pegylated-interferon alfa 2a (PegIFN);   Drug: Ribavirin (RBV)
9 Recruiting HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network
Condition: Hepatitis C
Intervention:
10 Recruiting Open-Label Study of GS-7977+ Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
Condition: Chronic Hepatitis C
Interventions: Drug: GS-7977 in combination with ribavirin;   Drug: GS-7977 400mg QD+ RBV BID+ PEG
11 Recruiting A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
Conditions: Hepatitis B;   HBV
Interventions: Drug: Single Ascending Dose (SAD) Cohorts GS-9620;   Drug: Multiple Ascending Dose (MAD) Cohorts
12 Recruiting A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Condition: Hepatitis B
Interventions: Drug: Single Ascending Dose (SAD) Cohorts GS-9620;   Drug: Multiple Ascending Dose (MAD) Cohorts GS-9620
13 Recruiting Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Condition: Hepatitis B Virus
Interventions: Drug: pegIFN;   Drug: pegIFNα-2a;   Drug: PegIFN lambda;   Drug: Entecavir
14 Recruiting Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Condition: Hepatitis C, Genotype 1
Interventions: Drug: BMS-790052 (Daclatasvir);   Drug: Ribavirin;   Drug: Peg-Interferon alfa 2a
15 Recruiting Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Endometrial Papillary Serous Carcinoma;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Ovarian Carcinosarcoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Papillary Serous Carcinoma;   Pancreatic Alpha Cell Adenoma;   Pancreatic Alpha Cell Carcinoma;   Pancreatic Beta Islet Cell Adenoma;   Pancreatic Beta Islet Cell Carcinoma;   Pancreatic Delta Cell Adenoma;   Pancreatic Delta Cell Carcinoma;   Pancreatic G-cell Adenoma;   Pancreatic G-cell Carcinoma;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Regional Gastrointestinal Carcinoid Tumor;   Stage IIIA Endometrial Carcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Endometrial Carcinoma;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Endometrial Carcinoma;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma;   Uterine Carcinosarcoma
Interventions: Drug: temsirolimus;   Biological: bevacizumab
16 Recruiting Ph I Dose Escalation Study of Antibody-drug Conjugate IMMU-132 in Patients With Advanced Epithelial Cancers
Conditions: Advanced Epithelial Cancers;   Ovarian Cancer;   Prostate Cancer;   Lung Cancer;   Breast Cancer;   Gastric Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Hepatocellular Cancer
Intervention: Drug: IMMU-132
17 Recruiting Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Condition: Hepatic Veno-Occlusive Disease
Intervention: Drug: Defibrotide
18 Unknown † Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
Conditions: Thrombocytopenia;   Hepatitis C;   HIV Infections
Intervention: Drug: Anti-D
19 Recruiting Spectroscopy With Surface Coils and Decoupling
Conditions: Adrenal Cortical Cancer;   Brain Cancer;   Breast Cancer;   CNS Cancer;   Colon Cancer;   HEENT Cancer;   Hodgkin's Disease;   Kaposi's Sarcoma;   Liver Cancer;   Lung Cancer;   Non-Hodgkin's Lymphoma;   Ovarian Cancer;   Pancreatic Cancer;   Prostate Cancer;   Rectal Cancer;   Renal Cancer;   Sarcoma;   Squamous Cell Carcinoma;   Thyroid Cancer
Interventions: Device: Proton-decoupled 31P MRS at 1.5T;   Device: 1H Spectroscopy at 1.5T and 3T
To Top

† Indicates status has not been verified in more than two years